A short version. The pencil that replaced the scissors. The fat bubble that smuggles it into the liver. The baby in Pennsylvania who got a one-of-one medicine. And why this may be the most consequential drug-class shift since the antibody.

A short version. How a hormone borrowed from lizard venom became the fastest-growing drug class in history, why the same playbook now points at longevity, addiction, cancer, and brain disease, and where designed peptides go next.

A short version. What Yamanaka discovered in 2006, why partial reprogramming may rewind biological aging, the four-billion-dollar race now chasing it, and what a real win looks like.

In CRISPR's original form, the editor is a pair of molecular scissors. The newer tools rewrite single letters of DNA without cutting at all — and the first ones are now reaching the bloodstream, the liver, and a Pennsylvania baby named KJ. An essay on what base editing is, how it differs from CRISPR and prime editing, why Eli Lilly bet $1B on Verve's PCSK9 program, and where programmable medicine goes next.

GLP-1 drugs like Ozempic and Mounjaro made peptides the fastest-growing class of medicines in history — and a near-trillion-dollar industry. An essay on what these molecules are, how chemists made a two-minute hormone last a week, and where the next wave is going.

In 2006, Shinya Yamanaka showed that four proteins can wind a grown-up cell back to an embryo-like state. The bet underneath today's longevity gold rush, including Altos Labs at $3B, Retro Biosciences, and NewLimit, is that you can do that *partway*, recovering youth without erasing the cell's identity.